finally, we expect adjusted diluted earnings per share to be in the range of $num-one to $num-two and reported diluted earnings per share to be in the range of $num-three to $num-four.
adjusted net income is expected to be in the range of $num-one billion to $num-two billion, representing operational growth of num-three% to num-four%.
for year-seven, we are projecting revenue between $num-one billion and $num-two billion, representing num-three% to num-four% operational growth.
we posted another strong quarter with revenue of $num-one billion, representing an increase of num-two% on both a reported and operational basis.
our livestock business declined num-one% in the quarter as a result of generic competition for draxxin unfavorable market conditions in the u.s., primarily resulting from elevated input costs as well as softer conditions in china, loss driven by reduced pork prices.
from a segment perspective, we saw solid balance across our global footprint with the u.s. up num-one% and international growing num-two% operationally.
year-six was an exceptional year for us with revenue of $num-one billion and adjusted net income of $num-two billion both exceeding the high end of our november full year guidance range.
simparica trio posted revenue of $num-one million, representing operational growth of num-two% versus the comparable year-five period and the third consecutive quarter with sales exceeding $num-three million.
u.s. revenue grew num-one%, with companion animal products growing num-two% and livestock sales declining by num-three%.
we grew revenue num-one% operationally, which is once again above the anticipated growth rate for the animal health market, and these results were highlighted by num-two% operational growth in our companion animal portfolio with num-three% operational growth in livestock.
u.s. livestock fell num-one% in the quarter, primarily resulting from our cattle business which, as expected, was challenged by generic competition for draxxin as well as elevated input costs continuing to weigh on producer profitability.
as a result, we are guiding to full year operational growth of num-one% to num-two% in revenue.
meanwhile, our key dermatology products, apoquel and cytopoint, again, had significant global growth in the quarter with $num-one million of revenue, representing num-two% operational growth against a robust prior year in which key derm grew num-three% in the fourth quarter of year-five.
based on the strong revenue performance, we were able to deliver num-one% operational growth in adjusted net income for the year while investing significantly in our latest product launches as well as staffing, r&d, and manufacturing projects for future growth.
full year revenue grew num-one% on a reported basis and num-two% operationally with adjusted net income increasing num-three% on a reported basis and num-four% operationally.
performance in companion animal was led by our small animal parasiticide portfolio bolstered by full year sales of simparica trio, which generated revenue of $num-one million, an increase of $num-two million compared to year-five sales.